World Money Crisis Causes India’s Piramal To Delay Raising Funds
This article was originally published in PharmAsia News
Executive Summary
India's Piramal Life Sciences says it has to put off launching a strategic stake sale as a way to raise funds, citing the global financial crisis. PLSL used to be the research and development arm of Piramal Healthcare until it was split off. Swati Piramal, director of the Piramal Group, said PLSL does not need immediate funds to continue operating, so it will defer its fund-raising plans until the world financial situation improves. (Click here for more
You may also be interested in...
Piramal’s Buyout Of Minrad May Dent Strongholds Of Abbott, Baxter
MUMBAI - Abbott and Baxter are set to face strong competition in their traditional businesses of hospital anesthetic gas products as India's Piramal Healthcare has announced its acquisition of U.S. based Minrad International, a provider of generic inhalation anesthetics that include isoflurane, enflurane and sevoflurane. In addition, Minrad has filed an abbreviated new drug application for desflurane with U.S. FDA
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.